Circulating myomiRs in Muscle Denervation: From Surgical to ALS Pathological Condition

ALS is a fatal neurodegenerative disease that is associated with muscle atrophy, motoneuron degeneration and denervation. Different mechanisms have been proposed to explain the pathogenesis of the disease; in this context, microRNAs have been described as biomarkers and potential pathogenetic factors for ALS. MyomiRs are microRNAs produced by skeletal muscle, and they play an important role in tissue homeostasis; moreover, they can be released in blood circulation in pathological conditions, including ALS. However, the functional role of myomiRs in muscle denervation has not yet been fully clarified. In this study, we analyze the levels of two myomiRs, namely miR-206 and miR-133a, in skeletal muscle and blood samples of denervated mice, and we demonstrate that surgical denervation reduces the expression of both miR-206 and miR-133a, while miR-206 but not miR-133a is upregulated during the re-innervation process. Furthermore, we quantify the levels of miR-206 and miR-133a in serum samples of two ALS mouse models, characterized by different disease velocities, and we demonstrate a different modulation of circulating myomiRs during ALS disease, according to the velocity of disease progression. Moreover, taking into account surgical and pathological denervation, we describe a different response to increasing amounts of circulating miR-206, suggesting a hormetic effect of miR-206 in relation to changes in neuromuscular communication.

[1]  A. Musarò,et al.  A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients , 2021, Cell death discovery.

[2]  A. Musarò,et al.  Neuromuscular magnetic stimulation counteracts muscle decline in ALS patients: results of a randomized, double-blind, controlled study , 2019, Scientific Reports.

[3]  H. Weiner,et al.  Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis , 2018, Muscle & nerve.

[4]  C. Bernardini,et al.  Skeletal Muscle MicroRNAs as Key Players in the Pathogenesis of Amyotrophic Lateral Sclerosis , 2018, International journal of molecular sciences.

[5]  J. Bienertová-Vašků,et al.  Muscle-specific microRNAs in skeletal muscle development. , 2016, Developmental biology.

[6]  N. Tran,et al.  Circulating microRNAs: potential biomarkers for common malignancies. , 2015, Biomarkers in medicine.

[7]  Raquel Manzano,et al.  MicroRNA-206: A Potential Circulating Biomarker Candidate for Amyotrophic Lateral Sclerosis , 2014, PloS one.

[8]  L. Greensmith,et al.  Rodent models of amyotrophic lateral sclerosis. , 2013, Biochimica et biophysica acta.

[9]  A. Musarò Understanding ALS: new therapeutic approaches , 2013, The FEBS journal.

[10]  V. Meininger,et al.  Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. , 2013, Brain : a journal of neurology.

[11]  B. Kalmar,et al.  A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis , 2011, Disease Models & Mechanisms.

[12]  D. Cacchiarelli,et al.  MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. , 2010, Cell metabolism.

[13]  S. Jeng,et al.  Profiling muscle-specific microRNA expression after peripheral denervation and reinnervation in a rat model. , 2009, Journal of neurotrauma.

[14]  John McAnally,et al.  MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice , 2009, Science.

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.